Can I buy BPC-157 in the UK? The regulations, quoted

Written by Free Muscle · Published by a seller of these compounds · Last updated

Can I buy BPC-157 in the UK? The honest answer is that the question turns on the Human Medicines Regulations 2012, which prohibit selling an unauthorised medicinal product, and that we could find no statement naming BPC-157 from the MHRA or UK Anti-Doping. Whether a given product falls within the regulations is a legal question, and this is general information, not legal advice. BPC-157 research itself is a patchwork of rat experiments, cell-culture work and a handful of very small human reports. BPC-150 is the designation Free Muscle uses for one of its own listings. This guide quotes the legislation, sets out what regulators and anti-doping bodies have and have not said, explains what the published literature does and does not show, and describes how to judge the quality of any research material, including how ordering works at Free Muscle. It is educational only.

Key takeaways

  • BPC-157 and BPC-150 are not the same name. BPC-157 is the 15-amino-acid peptide described in the scientific literature. BPC-150 is Free Muscle's own designation, and our PubMed search for "BPC-150" on 2 October 2026 returned no records. Nothing in the literature can be transferred to the product.
  • Most BPC-157 research is preclinical. The efficacy findings come mainly from rat experiments, together with cell-culture work.
  • Human data are thin. Reviewers count three small, uncontrolled pilot reports, all involving injections or an intravenous infusion, and none is a randomised controlled trial.
  • Regulators and anti-doping bodies are cautious. The statements quoted below describe the compound as unapproved and as having limited safety information.
  • The BPC-157 UK legal position. Selling an unauthorised medicinal product is prohibited under the Human Medicines Regulations 2012. Whether a given product falls within that definition is a legal question. This is general information, not legal advice.
  • Quality is about documents. A Certificate of Analysis from a named independent laboratory, matched to the batch number on the label, is the main way to judge identity and purity.

This section sets out only what could be verified from primary sources about the legal position of BPC-157 in the UK, and it stops where the verified facts stop.

What the legislation says

Under regulation 2 of the Human Medicines Regulations 2012, a substance that may be used by or given to people to restore, correct or modify a physiological function through a pharmacological, immunological or metabolic action is a "medicinal product". Regulation 46(1), on the sale and supply of unauthorised medicinal products, states that a person may not sell, supply or offer to sell or supply an unauthorised medicinal product.

Whether a given material meets the regulation 2 test is a legal question for a lawyer or the regulator, and this article does not answer it. This is general information, not legal advice.

What we could not find

A search of gov.uk for BPC-157 returned no relevant result, and we found no statement about BPC-157 from the Medicines and Healthcare products Regulatory Agency (MHRA) or from UK Anti-Doping. Absence of a search result is not proof that no such page exists, so the correct reading is that we do not know of a UK regulator statement and therefore do not attribute one. We also make no claim that any UK authority classifies BPC-157 or BPC-150 as a medicine.

The UK guidance on advertising medicines says, among other things, that medicine advertising must not suggest that effects are guaranteed. It is written for medicines, and whether it applies to a given product is a legal question the page does not settle.

Statements from outside the UK

The United States Anti-Doping Agency (USADA) states on its USADA BPC-157 page that the compound is prohibited under the S0 "Non-Approved Substances" category of the World Anti-Doping Agency list and is not approved for human clinical use by the US Food and Drug Administration or any other global health authority. USADA also says there are no human clinical trials establishing efficacy for any diagnosis, and that it is not known whether any dose is without harm. USADA does not mention the three small uncontrolled pilot reports described below.

One 2025 literature review in Pharmaceuticals reaches a different conclusion about listing status, saying the peptide was temporarily banned in 2022 and is not currently listed (Józwiak et al., 2025). We could not read the current list text directly, so anyone subject to anti-doping rules should check the current World Anti-Doping Agency website and UK Anti-Doping guidance themselves.

The FDA includes BPC-157 on its page on substances that may present significant safety risks in compounding, under the sub-list of substances nominated but withdrawn. The agency says it has identified little or no safety-related information for the proposed routes and cannot tell whether harm would result. That is a US compounding statement, not a UK one, and the FDA has not "banned" the peptide on that page.

This is general information, not legal advice.

The position for the other compounds we stock, side by side: Are SARMs legal in the UK? 2026 guide

What "research use only" means, and what it does not

Free Muscle sells research compounds for laboratory research use only, to customers aged 18 or over. They are not medicines or food supplements and they are not for human consumption. Nothing on the site or in this article is medical advice. The product page for BPC-150 1000mg, 60 capsules is marked research use only and not for human consumption, says it is not authorised as a medicine or a food supplement in the UK or EU, and adds that human clinical evidence is essentially absent.

What the label does not do

  • It does not decide the legal question, which turns on the legislation quoted above and is for a lawyer or the regulator to answer.
  • It does not prove identity or purity. Those need independent testing, covered further down.
  • It does not turn animal or cell findings into human evidence.
  • It does not mean regulators have reviewed the material.

The Free Muscle listing also states that the product is "Marketed as a variant of BPC-157". That wording is the seller's own, and the wording describes a marketing relationship, not an established chemical identity. No study named BPC-150 was found, and nothing in the sources checked verifies that the capsule contains the literature peptide. For the same reason, every finding below is reported as a finding about BPC-157, in the named population, and not about the product.

What researchers and regulators say

Forum posts and personal accounts are not evidence, and this guide does not use them. What follows is peer-reviewed literature, regulators and anti-doping bodies. Each result below describes what happened to the named animals, cells or patients in the named study, and each section of findings is paired with the limitations of that evidence.

Animal and cell studies: where most BPC-157 research sits

In rats whose Achilles tendon had been cut, injections of BPC-157 into the abdominal cavity were followed by a higher load to failure, higher Achilles functional index values, and, under the microscope, more fibroblast, reticulin and collagen formation and fewer granulocytes than saline in the same model (Staresinic et al., 2003). A later paper in rats with a cut medial collateral ligament tested intraperitoneal injection, a topical cream and the peptide in drinking water, and reported functional, biomechanical, macroscopic and histological improvements with each (Cerovecki et al., 2010). The protocol details are in those papers and are deliberately not repeated here.

Mechanisms have been studied in cell culture. In cultured rat tendon fibroblasts, BPC-157 sped the outgrowth of cells from tendon explants and improved cell survival under oxidative stress, without directly increasing cell proliferation. The authors linked the effect to activation of the FAK-paxillin pathway (Chang et al., 2011). A later study reported more blood vessels in a chick membrane assay and in endothelial cells, faster restoration of blood flow in ischaemic rat hind-limb muscle, and activation of a VEGFR2-Akt-eNOS signalling route (Hsieh et al., 2017).

Limitations of this layer. These are rats, chick embryos and cultured cells, not people. A 2025 short article in Inflammopharmacology discusses one very long review of the peptide (Whitehouse, 2025), and its abstract offers no findings, so it is not relied on here. A 2006 review (Sikiric et al., 2006) refers to inflammatory bowel disease trials in its title and abstract, but the abstract reports no trial results. USADA separately says studies of BPC-157 appear to have been cancelled or stopped without published conclusions.

Safety and pharmacokinetics in animals

Toxicology work in mice, rats, rabbits and dogs reported that single-dose testing showed no test-related effects, repeated dosing produced no abnormal changes in dogs apart from a fall in creatinine at one dose level but not at lower levels, and the animals returned to normal after a two-week withdrawal. Local irritation was mild, and tests for genetic and embryo-fetal toxicity were negative (Xu et al., 2020). A pharmacokinetic study in rats and beagle dogs measured the peptide after intravenous and intramuscular dosing. The half-life of the intact peptide was under 30 minutes, absolute bioavailability after intramuscular injection was about 14 to 19 per cent in rats and 45 to 51 per cent in dogs, and the peptide was broken down quickly into small fragments and single amino acids (He et al., 2022).

Limitations. These are animal data. The pharmacokinetic study used injections only. A 2026 biopharmaceutics review points to a disconnect between a half-life under 30 minutes and the long-lasting biological effects reported in animals, and says human pharmacokinetics remain critically under-characterised (Mateescu et al., 2026).

The human reports

Lee and colleagues reported three small studies, which make up the human literature that reviewers count. The knee study was done at a clinic in Orlando, Florida, and the intravenous report at a private clinic in Florida.

  • Knee pain (Lee and Padgett, 2021). A retrospective chart review of 17 patients, 16 of whom were reached by telephone. Twelve had received BPC-157 alone as an injection into the knee joint, and 11 of those 12 reported significant improvement. Four had received BPC-157 with thymosin beta-4, and overall 14 of 16 reported relief. There was no control group, and the authors state that no tools were used to measure function, stiffness or quality of life.
  • Interstitial cystitis (Lee et al., 2024). Twelve women whose symptoms had not responded to another treatment were given injections around the inflamed bladder area during one cystoscopy procedure, using material from a compounding pharmacy. Ten of 12 reported complete resolution on a questionnaire, two reported most symptoms resolved, and no adverse events were reported. The report describes a single group of twelve women; reviewers class the three pilots as uncontrolled (Mateescu et al., 2026).
  • Intravenous tolerability (Lee and Burgess, 2025). Two adults had blood tests and vital signs checked around infusions. The report found no measurable changes in the tested heart, liver, kidney, thyroid or glucose markers and no reported side effects. The authors state that further studies are needed to confirm the intravenous findings, and note that both participants had received intravenous BPC-157 before the study.

Limitations. The reviewers cited here describe the human data as extremely limited, and say rigorous large-scale trials are lacking (McGuire et al., 2025). The outcomes were largely patient-reported, and reviewers class the pilots as uncontrolled. A 2025 systematic review describes a retrospective intra-articular knee study (its abstract does not name it, but it appears to be the same one) as 7 of 12 patients reporting relief for more than six months, which is a different outcome from the 11 of 12 reporting significant improvement in the original abstract (Vasireddi et al., 2025). The same review identified 544 articles and included 36 studies (35 preclinical, 1 clinical) at level IV and V, searched to 3 June 2024, and reported that no clinical safety data were found. A 2025 narrative review found only three human pilot studies, said rigorous large-scale trials are lacking, and advised that BPC-157 be considered investigational (McGuire et al., 2025, above). A 2026 review also counts three uncontrolled pilots (Mateescu et al., 2026, above). It adds that the clinical data come from fewer than 30 subjects using non-standard preparations, with no approved formulation, no validated dosing regimen and no completed Phase II trial. The individual reports total about 30 people (2, 12 and 17), so the reviewers' “fewer than 30” is an approximate figure.

Our ClinicalTrials.gov search found two registered trials of injected BPC-157: a randomised, double-blind, placebo-controlled Phase 2 trial in hamstring strain (NCT07437547), listed as recruiting on 2 October 2026 and planned for 120 participants, and a small Phase 1 pilot in rotator cuff repair that had not yet started recruiting (NCT07803250). Neither has results.

Evidence quality: what the reviews say

The 2025 systematic review describes itself as a review of level IV and level V studies (Vasireddi et al., 2025). The 2026 Sports Medicine review discusses the placebo effect as a mediator of peptide efficacy and how social media amplifies it (Mendias and Awan, 2026). Reviewers describe the three human pilots as uncontrolled (Mateescu et al., 2026). A structured 2026 review in JBJS Reviews describes regenerative peptides including BPC-157 as investigational, with uncertain safety profiles, product-quality concerns and widespread anti-doping restrictions (Villegas Meza et al., 2026).

Safety concerns raised in reviews

A 2026 safety review of unregulated injectable products lists product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis and cardiovascular stress among the risks the authors describe for unregulated substances that lack established human safety profiles, a group that includes BPC-157 (Moiz et al., 2026). The 2025 systematic review similarly says adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety. Both are reasons why independent testing of material matters, discussed below.

Oral versus injection: an important caveat

Every human report above involved an injection or an infusion, and both of those registered trials use injections. The animal route data are mixed: in rats the peptide was reported to work when added to drinking water (Cerovecki et al., 2010), and the biopharmaceutics review notes unusual stability in gastric juice and activity by oral, injected and topical routes in animals. That review also says the human profile is critically under-characterised, and the pharmacokinetic study above measured only injections. No oral absorption measurement in people is reported in the abstracts we reviewed. The biopharmaceutics review also mentions a preliminary two-subject human pilot; its abstract does not state the route, so we do not rely on it for any statement about capsules. Results from injection studies or from rats drinking treated water cannot therefore be assumed for a capsule. Our guide to oral peptides and why the route of administration matters sets out the general digestion and absorption problem for peptides.

Anti-doping science

Because BPC-157 appears on anti-doping radar, analytical chemists have published detection work. Cox and colleagues identified the peptide in confiscated vials and validated a urine detection method (Cox et al., 2017). A later mass-spectrometry study characterised the in vitro metabolic profile and validated a method to detect the peptide and five main metabolites in human urine (Tian et al., 2023). Neither is evidence of benefit or harm. Both show that laboratories can identify the peptide, and that anyone subject to testing has a practical reason to check the rules.

How to judge quality: the Certificate of Analysis explained

A Certificate of Analysis (COA) is a laboratory report on one batch of material. Reading it well does not need a chemistry degree. Our guide on how to read a Certificate of Analysis explains step by step how to read one, and the table below summarises the checks.

What to check What it tells you Red flag
Named laboratory Who did the testing, and whether they are independent of the seller. A lab name lets you contact the lab to confirm the report exists. No lab named, a logo only, or a lab that cannot be identified.
Batch number matching the label Whether the report refers to the same batch as the bottle in front of you. A batch number that differs from the label, is missing, or is the same on every report.
Test date Whether the report is recent relative to the batch, and whether it belongs to that production run. No date, a date long before the batch could have been made, or an edited-looking document.
Identity by mass spectrometry Mass spectrometry measures the weight of molecules, so it shows whether the main component has the expected molecular mass. For BPC-157 the literature gives a molecular weight of about 1419 (Staresinic et al., 2003). No identity test at all, or a measured mass that does not match the expected figure.
Purity by HPLC High-performance liquid chromatography separates a sample into components and reports the share of the main peak. It tells you how much of the detected material is the main compound, not whether it is suitable for any use. No chromatogram, a purity figure with no trace to support it, or a large unexplained secondary peak.
Product name and strength Whether the report describes the product you bought, in the form you bought it. A generic report for a different compound, form or pack.
How the report was obtained Whether the seller sends it for your batch, or shows one stock document. A single report reused for every batch, or a refusal to supply one.

Two cautions apply. First, a COA describes the material that was tested, so it supports identity and purity claims about that batch and nothing more. It is not a statement about any use, and it does not turn research material into a medicine. Second, the identity test only answers the question it was designed to answer. For a product sold under the designation BPC-150, the report is the way to find out what the batch actually contains, which is why it is worth asking for.

How batch testing works at Free Muscle

Every Free Muscle batch of research compounds is assayed for identity and purity by Janoshik Analytical, an independent laboratory. The Certificate of Analysis for a batch is sent on request. To ask for one, email the batch number printed on the label together with the product name. The process is described on the Free Muscle lab tests page.

How to order from Free Muscle, step by step

  1. Choose the listing. Browse the research peptides collection or go straight to the product page, and read the description in full, including the research-use-only wording and the statement about the lack of human evidence.
  2. Add to basket and check out. Add the item to your basket and follow the standard checkout steps. Check pack size and strength on the page before paying.
  3. Age. Research compounds are sold only to customers aged 18 or over.
  4. Delivery. UK delivery is free and tracked, in plain packaging. Standard UK delivery takes 2 to 5 working days. Orders placed before 2pm UK time, Monday to Friday, are processed the same working day. Full details are on the shipping information page.
  5. Check the label on arrival. The batch number is printed on the label. Keep it, as it is what you quote to request the COA.
  6. Request the Certificate of Analysis. Email the batch number from the label together with the product name, as described on the lab tests page.
  7. Returns. Unopened items in their original packaging can be returned within 30 days under the returns terms on the returns page. For apparel, see the refund policy.

A note on terms: the Free Muscle listing is for BPC-150, which is the company's own designation. The page describes it as marketed as a variant of BPC-157, and the BPC-157 literature should not be assumed to apply to it.

The listing referred to in this guide is BPC-150 1000mg, 60 capsules. The product page and the printed label are the authority on how the strength is expressed, so check them before ordering.

Frequently asked questions

Is BPC-157 legal in the UK?

On the BPC-157 UK question, we could not find a UK regulator statement naming BPC-157. The legislation prohibits selling unauthorised medicinal products, and a substance with a pharmacological, immunological or metabolic action on a physiological function can fall within the definition. Whether a particular product does is a legal question. This is general information, not legal advice.

Why does Free Muscle call it BPC-150?

BPC-150 is Free Muscle's own designation, and the product page describes it as marketed as a variant of BPC-157. Our PubMed search for "BPC-150" on 2 October 2026 returned no records, so no published research on a compound of that name was found. The batch Certificate of Analysis is the way to see what was tested.

Can I buy BPC-157 in the UK?

We cannot give a legal answer to "can I buy BPC-157 in the UK?", and this is general information, not legal advice. The legislation linked above prohibits selling or supplying unauthorised medicinal products, and whether a particular substance counts as one is a legal question. Free Muscle lists a product under its own designation BPC-150, which its product page describes as marketed as a variant of BPC-157. It is sold for laboratory research use only to customers aged 18 or over and is not for human consumption.

What does "research use only" mean?

It means the material is sold for laboratory research, to adults aged 18 or over. It is not a medicine or food supplement and is not for human consumption. See the section above for what the label does not do.

How do I know the purity of a batch?

Ask for the Certificate of Analysis for your batch. Check that the laboratory is named, that the batch number matches the label, that the date is plausible, and that both identity (mass spectrometry) and purity (HPLC) results are shown.

How do I request a Certificate of Analysis from Free Muscle?

Email the batch number printed on the label together with the product name. The process is described on the lab tests page.

Do I need to be a certain age to order?

Yes. Research compounds are sold only to customers aged 18 or over.

How much human evidence is there on BPC-157?

Reviewers count only three small, uncontrolled human pilot reports. A registered randomised, double-blind, placebo-controlled Phase 2 trial in hamstring strain (NCT07437547) was listed as recruiting on 2 October 2026. Most of the evidence is from animals and cells, which is why reviewers describe the peptide as investigational.

Where can I read the full studies?

Every published study cited here is linked to its PubMed record in the sources list below.

Sources

  1. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  2. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
  3. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
  4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi PMID 40756949
  5. McGuire FP, Martinez R, Lenz A, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi PMID 40789979
  6. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2). doi PMID 40005999
  7. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi PMID 41966639
  8. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5). doi PMID 42198317
  9. Villegas Meza AD, Nocek M, Mitchell BC, et al. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications. JBJS Rev. 2026;14(5). doi PMID 42160466
  10. Moiz A, O'Keefe EL, O'Keefe JH. Dangers of injectable peptides and other unregulated "biohacking" drugs. Mo Med. 2026;123(4):337-343. PMID 42757290
  11. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi PMID 14554208
  12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi PMID 21030672
  13. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi PMID 27847966
  14. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi PMID 20225319
  15. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi PMID 32334036
  16. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi PMID 36588717
  17. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. doi PMID 28035768
  18. Tian T, Jing J, Li Y, et al. Stable isotope labeling-based nontargeted strategy for characterization of the in vitro metabolic profile of a novel doping BPC-157 in doping control by UHPLC-HRMS. Molecules. 2023;28(21). doi PMID 37959764
  19. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi PMID 17186181
  20. Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology. 2025;33(8):4879-4881. doi PMID 40759852
  21. Human Medicines Regulations 2012, regulations 2 and 46. legislation.gov.uk.
  22. Advertise your medicines. gov.uk.
  23. FDA page on compounding safety risks. US Food and Drug Administration, page current as of 22 April 2026.
  24. USADA, "BPC-157 peptide prohibited" page (Spirit of Sport), read on 2 October 2026.
  25. NCT07437547. ClinicalTrials.gov record, read on 2 October 2026.
  26. NCT07803250. ClinicalTrials.gov record, read on 2 October 2026.
  27. PubMed search for "BPC-150" (pubmed.ncbi.nlm.nih.gov), run on 2 October 2026; it returned no records.
Notice. This article is published by Free Muscle, which sells the research compounds discussed. They are sold for laboratory research use only, to customers aged 18 or over. They are not medicines or food supplements and are not for human consumption. This is not medical advice, and it is general information, not legal advice. Find more in the Free Muscle range.

Ghiduri conexe